Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
- NCT03534323 ↗
- Completed
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on NCT03534323 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03534323 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Chronic Lymphocytic Leukemia; Richter Syndrome
- Interventions
- Duvelisib; Venetoclax
- Arms
- Phase 1 Level 1: 100 mg Venetoclax (daily) + 25 mg Duvelisib (BID) · Experimental
- Phase 1 Level 2: 200 mg Venetoclax (daily) + 25 mg Duvelisib (BID) · Experimental
- Phase 1 Level 3: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID) · Experimental
- Phase 2: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID) · Experimental
- Enrollment
- 55
- Primary outcomes
- Complete Response Rate (CRR)
- Overall Response Rate (ORR)
- Sponsor
- Dana-Farber Cancer Institute with Secura Bio, Inc.
- Start
- Jul 12, 2018
- Primary completion
- Dec 1, 2024
- Results posted
- Yes
- Registry record
- NCT03534323 · updated Oct 28, 2026
Publications
linked from the registry- Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS. A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. Blood Adv. 2026 Jun 9;10(11):3811-3819. doi: 10.1182/bloodadvances.2025018878. PubMed 41886642